AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32671481
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)
Trial: 35507499
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy plus ICD
Trial: 34658253
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion to mimic prandial insulin response (full dose, 80% dose, 60% dose)
Trial: 34658253
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 0.65 ng/kg/min (nonsuppressed day)
Trial: 34658253
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 0.65 ng/kg/min (suppressed day)
Trial: 34658253
Drug: Multivariate regression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivariate regression analysis adjusted for age, sex, weight, and insulin dose
Trial: 34954718
Drug: Monthly HIV
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly HIV self-testing and quarterly in-clinic testing
Trial: 32533548
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) for eight sessions
Trial: 32533548
Drug: Conventional medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medications and psycho-education (control group)
Trial: 35383832
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily
Trial: 36244667
Drug: Dexmedetomidine (DEX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (DEX, 0.6 μg/kg)
Trial: 33612197
Drug: Behavioral self-control
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral self-control therapy (BSCT)
Trial: 34724084
Drug: Individual nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual nutritional counseling every 2 weeks during therapy
Trial: 34774334
Drug: Etelcalcetide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide (5 mg per dose intravenously)
Trial: 33435287
Drug: Controlled-feeding Continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-feeding Continuous Energy Restriction (CER) - 25% daily energy restriction
Trial: 35266148
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (POIT) with AR101
Trial: 35266148
Drug: AR101 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AR101 therapy
Trial: 32539121
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (initial dose of 10 mg/kg followed by 5 mg/kg after 24 hours and a second 5 mg/kg dose after 48 hours)
Trial: 34273071
Drug: All other
RxNorm normalized name: ALL OTHER THERAPEUTIC PRODUCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All other azole antifungals
Trial: 36335411
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or sublingual mixed respiratory bacterial lysates (BLs)
Trial: 36335411
Drug: Injected mixed
RxNorm normalized name: Humalog Mix Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected mixed respiratory bacterial vaccines (BVs)
Trial: 33730122
Drug: Nerve Growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve Growth Factor (NGF) injection into SCM
Trial: 33730122
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution injection into SCM
Trial: 35043507
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered purified clinoptilolite-tuff (PCT)
Trial: 32757963
Drug: PCT-guided discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided discontinuation of antimicrobials
Trial: 32823510
Drug: Dietary practices
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary practices of adolescents (e.g., sugary snacks, breakfast consumption)
Trial: 36261400
Drug: O-R toothbrush
RxNorm normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-R toothbrush (Oral-B iO with Radiant White brush head)
Trial: 36261400
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B Indicator)
Trial: 34254372
Drug: Cornus mas
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cornus mas L. fruit extract (CMFE)
Trial: 35006328
Drug: Carbohydrate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate therapy (CHO) group received a 400‐mL carbohydrate drink 2‐3 hours before anesthesia
Trial: 35006328
Drug: Carbohydrate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate therapy (CHO) group
Trial: 34760020
Drug: Garlic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplementation (one tablet daily for three consecutive cycles)
Trial: 34760020
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet daily for three consecutive cycles)
Trial: 36184780
Drug: tirzepatide 5
RxNorm normalized name: tirzepatide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirzepatide 5 mg
Trial: 36184780
Drug: tirzepatide 10
RxNorm normalized name: tirzepatide 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirzepatide 10 mg
Trial: 36184780
Drug: tirzepatide 15
RxNorm normalized name: tirzepatide 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirzepatide 15 mg
Trial: 35998958
Drug: Perioperative support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative support programme consisting of four face-to-face intervention sessions during the hospital stay and two weekly telephone follow-up sessions after discharge.
Trial: 34096755
Drug: Psychedelic-assisted psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychedelic-assisted psychotherapy (PAP) using compounds such as MDMA, psilocybin, and LSD
Trial: 32017253
Drug: Curcumin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1,000 mg/day for 3 months
Trial: 32617578
Drug: Aliskiren added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren added to an angiotensin II receptor blocker (ARB)
Trial: 36256673
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation with SCT
Trial: 36256673
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation with FET
Trial: 33827349
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Cycling Exercise on Land (HIIE-L)
Trial: 34101918
Drug: Sublingual dexmedetomidine
RxNorm normalized name: dexmedetomidine Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual dexmedetomidine
Trial: 33109218
Drug: Lucerastat 1000
RxNorm normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucerastat 1000 mg
Trial: 33109218
Drug: Lucerastat 4000
RxNorm normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucerastat 4000 mg
Trial: 33109218
Drug: Lucerastat (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucerastat (up to 4000 mg)
Trial: 35978342
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide for 12 weeks after culture conversion.
Trial: 35978342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide for 6 months.
Trial: 35978342
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin regimen.
Trial: 34762532
Drug: Low-level green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-level green laser (532 nm, 15 J/cm2 per treatment site)
Trial: 35962633
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (CON)
Trial: 36239176
Drug: Simultaneous implant
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous implant placement
Trial: 36239176
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement (control)
Trial: 35477518
Drug: Iberdomide 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide 0.45 mg
Trial: 35477518
Drug: Iberdomide (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.15 mg, 0.3 mg, 0.45 mg)
Trial: 33323914
Drug: Discordant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discordant treatment (DisTG)
Trial: 33323914
Drug: Concordant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concordant treatment (ConTG)
Trial: 34700768
Drug: Tumor Treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Treating Fields (TTFields) with individualized array placement, delivering doses over 2.5 mW/cm3
Trial: 34700768
Drug: Patient-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific treatment planning using numerical simulations
Trial: 34154034
Drug: Treatment failure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failure patients
Trial: 34138638
Drug: Imetelstat 9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat 9.4 mg/kg
Trial: 34138638
Drug: Imetelstat 4.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat 4.7 mg/kg
Trial: 35718440
Drug: 1% curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% curcumin nanomicelle gel
Trial: 34607863
Drug: Online chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online chronic disease self-management programme (CDSMP) plus medication adherence tools
Trial: 35322981
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium (5 mL)
Trial: 36449375
Drug: Subcutaneous fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fully closed-loop (FCL; CamAPS HX) insulin therapy
Trial: 36449375
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) insulin therapy
Trial: 33719017
Drug: Intranasal glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glulisine 20 IU twice daily
Trial: 32612186
Drug: Avocado pulp
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocado pulp (600 mg in capsule)
Trial: 32804855
Drug: 400 µg CrPic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg CrPic tablets (200 µg in two divided doses) daily for 12 weeks
Trial: 32087795
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide 25 mg once a day
Trial: 36578750
Drug: Transplantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplantation of autologous noncultured epidermal cell suspension (NCES) procedure done once
Trial: 35680097
Drug: Adjuvant intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravitreal therapy with 200 mg/ml 5-Fluorouracil (5-FU) and 5 IU/ml dalteparin (low-molecular weight heparin)
Trial: 35680097
Drug: Adjuvant intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravitreal therapy with 5-FU and LMWH
Trial: 34710343
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl 4 g daily
Trial: 32794478
Drug: Thumb spica
RxNorm normalized name: Thumb Spica Splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thumb spica cast with methylprednisolone acetate and xylocaine injection
Trial: 33141923
Drug: Firsocostat (FIR)
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Firsocostat (DB16166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firsocostat (FIR) 10 mg
Trial: 33141923
Drug: Firsocostat (FIR)
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Firsocostat (DB16166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firsocostat (FIR) 10 mg plus rifampin (RIF) 300 mg i.v.
Trial: 33141923
Drug: Rifampin (RIF)
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (RIF) 300 mg i.v. (control)
Trial: 34047372
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose genistein aglycone (160 mg/kg/day)
Trial: 33946072
Drug: Guided cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided cognitive-behavioral web-based intervention (WBI) + treatment as usual (TAU)
Trial: 38306042
Drug: Intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive BP treatment
Trial: 38306042
Drug: Standard BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP treatment
Trial: 32304001
Drug: Non-surgical conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical conventional treatment and diode laser application with wavelength of 980 nm (TG)
Trial: 32304001
Drug: Non-surgical conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical conventional treatment (CG)
Trial: 33438442
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with EPA-enriched oral supplement (1,000 mg/m2 gemcitabine on days 1, 8, and 15 every 4 weeks; EPA 1.056 mg per pack, maximum of two packs daily)
Trial: 33438442
Drug: Gemcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Trial: 33526709
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg SC every 2 weeks (q2w)
Trial: 33526709
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg SC every 4 weeks (q4w)
Trial: 35334418
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (n = 824)
Trial: 34630613
Drug: Compound Shenlu
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Shenlu granule (SLG) supportive group (group A, n = 44)
Trial: 32933356
Drug: myo-inositol supplementation
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: myo-inositol supplementation (2000 mg of myo-inositol and 200 μg of folic acid)
Trial: 33377611
Drug: Ranibizumab monthly
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monthly regimen (0.5 mg) from baseline to Month 11
Trial: 33377611
Drug: Ranibizumab PRN
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab PRN regimen (0.5 mg) from Month 12 to Month 23
Trial: 35321000
Drug: General oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General oxygen therapy
Trial: 32043344
Drug: Carbohydrate-electrolyte-protein solution
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte-protein solution (CEPS)
Trial: 35848336
Drug: OCS‐01 (dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCS‐01 (dexamethasone ophthalmic suspension), 1 drop 3 times/day for 12 weeks
Trial: 35848336
Drug: OCS‐01 (dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCS‐01 (dexamethasone ophthalmic suspension)
Trial: 33835383
Drug: GMB 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMB 120 mg
Trial: 33835383
Drug: GMB 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMB 240 mg
Trial: 33243380
Drug: TMVr with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302)
Trial: 34169381
Drug: Remote Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischemic Conditioning (RIC) administered daily for up to 15 days
Trial: 35523505
Drug: Multi-nutrient supplement
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient supplement (330 kcal, 20 g protein, 1.5 g calcium 3-hydroxy-3-methylbutyrate monohydrate, 449 mg calcium, 500 IU vitamin D3, and 25 vitamins and minerals)
Trial: 33563049
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acupuncture and medical training therapy
Trial: 33563049
Drug: All intervention
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All intervention groups (including acupuncture and medical training therapy)
Trial: 34224510
Drug: PO TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO TXA (1.95 g 2 hours preoperatively)
Trial: 34224510
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA (2 g: 1 g before incision and 1 g before wound closure)
Trial: 34769944
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (brochure and weekly mobile phone messages for six weeks)
Trial: 32212519
Drug: Fostemsavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (600 mg twice daily)
Trial: 32212519
Drug: Fostemsavir plus
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir plus optimized background therapy
Trial: 32212519
Drug: Open-label fostemsavir
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label fostemsavir plus optimized background therapy
Trial: 35864019
Drug: Tixel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixel treatment (thermomechanical skin device) applied across the upper and lower eyelids, three treatments with 2-week intervals.
Trial: 32956698
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (Arm 3)
Trial: 33443541
Drug: Sequential Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Chemoradiation (SCRT) - cisplatin 60-75 mg/m2 plus paclitaxel 135-175 mg/m2 in a 21-day cycle, given 2 cycles before and 2 cycles after radiotherapy.
Trial: 33443541
Drug: Concurrent Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Chemoradiation (CCRT) - weekly cisplatin 30-40 mg/m2.
Trial: 33443541
Drug: Radiation Alone
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation Alone (RT) - total dose 45-50 Gy.
Trial: 32803438
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser treatment with fluoride varnish
Trial: 34338132
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 36 µg
Trial: 34338132
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 18 µg
Trial: 34338132
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 9 µg
Trial: 34338132
Drug: Open-label tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label tiotropium 2.5 µg
Trial: 33094562
Drug: TXA (tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (tranexamic acid) 500 mg into the joint after closure, knee and hip flexed at 45° for 4 h